Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Liraglutide for managing overweight and obesity Guidance liraglutide Moreover, liraglutide combined with metformin did not increase the risk of hypoglycemia, but induced a higher incidence of gastrointestinal liraglutide We have previously demonstrated that a 12-week addition of liraglutide to insulin therapy in patients with type 1 diabetes results in

liraglutide Liraglutide belongs to the class of glucagon-like peptide 1 receptor agonist drugs, which increase glucose-dependent insulin